125290-83-7 Usage
Chemical class
Naphthyridine derivative
Functional groups
Carboxylic acid, cyclopropyl, fluoro, methyl, and ethyl ester
Potential applications
Pharmaceutical (antimicrobial and antifungal properties)
Structural modifications
Addition of cyclopropyl, fluoro, and methyl groups
Esterification
Ethyl ester formation
Bioavailability
Potentially improved compared to the parent compound
Pharmacokinetics
May be enhanced due to esterification
Research focus
Potential treatments for infectious diseases and other medical conditions
These properties and specific content are derived from the given material, which describes the compound as a derivative of naphthyridine with potential pharmaceutical applications. The addition of various functional groups and esterification may contribute to its pharmacological activity, bioavailability, and pharmacokinetics.
Check Digit Verification of cas no
The CAS Registry Mumber 125290-83-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,5,2,9 and 0 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 125290-83:
(8*1)+(7*2)+(6*5)+(5*2)+(4*9)+(3*0)+(2*8)+(1*3)=117
117 % 10 = 7
So 125290-83-7 is a valid CAS Registry Number.
125290-83-7Relevant articles and documents
Fluoronaphthyridines as Antibacterial Agents. 4. Synthesis and Structure-Activity Relationships of 5-Substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic Acids
Bouzard, D.,Cesare, P. Di,Essiz, M.,Jacquet, J. P.,Ledoussal, B.,et al.
, p. 518 - 525 (2007/10/02)
A series of 5-substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids have been prepared and tested for their in vitro and in vivo antibacterial activities.The 5-methyl group gave better in vitro activity with the 1-cyclopropyl appendage, but poorer activity with the 1-tert-butyl moiety.With the 1-(2,4-difluorophenyl) substitution, the influence of the 7-cycloalkylamino group was determinant: a (3S)-3-aminopyrrolidine was shown to enhance greatly the in vitro and in vivo activity of the 5-methyl derivative.Compound 33 (BMY 43748) was selec ted as a promising candidate for an improved therapeutic agent.
